KRTL Biotech Highlights ELIXIR as Flagship Hydration Product in Bolivia
KRTL Biotech (OTC: KRTL) has announced its flagship hydration product ELIXIR as a major success in the Bolivian market. The GMP-compliant hydration beverage is currently available in over 7,000 retail locations throughout Bolivia, offering a scientifically formulated blend of electrolytes including glucose, sodium, potassium, calcium, magnesium, and citric acid.
ELIXIR comes in multiple flavors and formats, from sachets to 625ml bottles, and has positioned itself as both a hangover recovery solution and cocktail mixer. The company is now preparing for international expansion, particularly targeting the U.S. market, and is working on regulatory compliance with FDA requirements for packaging, ingredient disclosures, and health claims.
KRTL Biotech (OTC: KRTL) ha annunciato il suo prodotto flagship per l'idratazione, ELIXIR, come un grande successo nel mercato boliviano. La bevanda idratante conforme alle GMP è attualmente disponibile in oltre 7.000 punti vendita in Bolivia, offrendo una miscela scientificamente formulata di elettroliti tra cui glucosio, sodio, potassio, calcio, magnesio e acido citrico.
ELIXIR è disponibile in molteplici gusti e formati, dai sachet alle bottiglie da 625 ml, e si è posizionato sia come soluzione per la recupero da postumi che come mixer per cocktail. L'azienda si sta ora preparando a espansione internazionale, in particolare mirando al mercato statunitense, e sta lavorando sulla conformità regolamentare con i requisiti FDA per l'imballaggio, la divulgazione degli ingredienti e le affermazioni sanitarie.
KRTL Biotech (OTC: KRTL) ha anunciado su producto insignia de hidratación, ELIXIR, como un gran éxito en el mercado boliviano. La bebida hidratante conforme a GMP está disponible actualmente en más de 7.000 puntos de venta en Bolivia, ofreciendo una mezcla científicamente formulada de electrolitos que incluye glucosa, sodio, potasio, calcio, magnesio y ácido cítrico.
ELIXIR viene en múltiples sabores y formatos, desde sachets hasta botellas de 625 ml, y se ha posicionado como una solución para la resaca y como mezclador de cócteles. La empresa se está preparando para una expansión internacional, apuntando especialmente al mercado de Estados Unidos, y está trabajando en el cumplimiento regulatorio con los requisitos de la FDA para el etiquetado, divulgación de ingredientes y afirmaciones de salud.
KRTL Biotech (OTC: KRTL)는 볼리비아 시장에서 자사 주력 수분 보충 제품 ELIXIR가 큰 성공을 거두었다고 발표했습니다. GMP 준수 수분 음료는 현재 볼리비아 전역의 7,000개 소매점에서 판매 중이며, 포도당, 나트륨, 칼륨, 칼슘, 마그네슘, 구연산으로 구성된 과학적으로 조합된 전해질 혼합물을 제공합니다.
ELIXIR는 다양한 맛과 포장 형식으로 제공되며, 파우치부터 625ml 병까지 다양합니다. 숙취 회복 솔루션 및 칵테일 믹서로 자리 잡았고, 이제 국제 확장을 준비 중이며 특히 미국 시장을 겨냥하고 있으며, 포장, 성분 공개, 건강 주장에 대한 FDA 요건을 충족하기 위한 규제 준수 작업을 진행 중입니다.
KRTL Biotech (OTC: KRTL) a annoncé son produit phare d'hydratation, ELIXIR, comme un grand succès sur le marché bolivien. La boisson hydratante conforme aux GMP est actuellement disponible dans plus de 7 000 points de vente à travers la Bolivie, offrant un mélange scientifiquement formulé d'électrolytes comprenant du glucose, du sodium, du potassium, du calcium, du magnésium et de l'acide citrique.
ELIXIR se décline en plusieurs saveurs et formats, des sachets aux bouteilles de 625 ml, et s'est positionné à la fois comme solution de récupération après gueule de bois et comme mélangeur de cocktails. L'entreprise se prépare désormais à une expansion internationale, ciblant particulièrement le marché américain, et travaille sur la conformité réglementaire avec les exigences de la FDA concernant l'emballage, la divulgation des ingrédients et les allégations de santé.
KRTL Biotech (OTC: KRTL) hat sein bahnbrechendes Hydratationsprodukt ELIXIR als großen Erfolg auf dem bolivianischen Markt angekündigt. Das GMP-konforme Hydratationsgetränk ist derzeit in über 7.000 Einzelhandelsstandorten in Bolivien erhältlich und bietet eine wissenschaftlich formulierte Mischung aus Elektrolyten, darunter Glukose, Natrium, Kalium, Kalzium, Magnesium und Zitronensäure.
ELIXIR ist in mehreren Geschmacksrichtungen und Formaten erhältlich, von Beuteln bis zu 625-ml-Flaschen, und hat sich sowohl als Lösung für Hangover-Erholung als auch als Cocktail-Mixer positioniert. Das Unternehmen bereitet sich nun auf eine internationale Expansion vor, insbesondere mit Blick auf den US-Markt, und arbeitet an der regulatorischen Einhaltung der FDA-Anforderungen bezüglich Verpackung, Offenlegung der Zutaten und Gesundheitsversprechen.
KRTL Biotech (OTC: KRTL) أعلنت عن منتجها الرائد للترطيب، ELIXIR، كنجاح كبير في السوق البوليفي. المشروب الترطيبي المتوافق مع GMP متاح حالياً في أكثر من 7,000 متجر تجزئة عبر بوليفيا، بتركيبة علمية من الكهارل تشمل الجلوكوز، الصوديوم، البوتاسيوم، الكالسيوم، المغنيسيوم وحمض الستريك.
ELIXIR يأتي بنكهات وشكليات متعددة، من أكياس إلى زجاجات 625 مل، وهو مخصص كحل للتعافي من pós-سكر؟ بعد شرب الكحول وتركيب كوكتيلات. تتهيأ الشركة حالياً لتوسع عالمي، خاصة في السوق الأمريكي، وتعمل على الامتثال التنظيمي لمتطلبات FDA بخصوص التعبئة وكشف المكونات والمطالبات الصحية.
KRTL Biotech (OTC: KRTL) 宣布其旗舰补水产品 ELIXIR 在玻利维亚市场取得重大成功。符合 GMP 的补水饮料目前在玻利维亚的超过 7,000 家零售点 有售，提供包括葡萄糖、钠、钾、钙、镁和柠檬酸在内的科学配方电解质混合物。
ELIXIR 有多种口味和包装格式，从粉包到 625 毫升瓶，定位为宿醉恢复解决方案及鸡尾酒混合调味。公司现正准备进行 国际扩张，特别瞄准美国市场，并正在按照 FDA 要求就包装、成分披露和健康声明进行法规合规工作。
- None.
- Currently limited to Bolivian market only
- Pending FDA regulatory approvals needed for U.S. market entry
- Will face significant competition in the saturated U.S. beverage market
Lakewood, CO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company") today announced that its subsidiary, KRTL Biotech, Inc., is spotlighting ELIXIR, a high-performance electrolyte hydration beverage, as one of its most commercially successful and strategically positioned consumer health products in the Bolivian Market
Produced under GMP-compliant conditions at KRTL Biotech’s Bolivian facility, ELIXIR is a non-alcoholic, hypertonic hydration beverage designed to rapidly restore essential electrolytes and combat dehydration caused by intense physical activity, heat exposure, or alcohol consumption. With a proprietary formula containing glucose, sodium, potassium, calcium, magnesium, and citric acid, ELIXIR is scientifically formulated to hydrate cells more efficiently than traditional sports drinks.
Currently available in more than 7,000 retail drugstores, major supermarkets, and club stores throughout Bolivia, ELIXIR has earned a reputation as both a hangover recovery essential and a popular mixer in cocktails. Its vibrant branding and broad consumer appeal have made it a mainstay in nightclubs, gyms, and family households alike.
"ELIXIR represents the intersection of scientific hydration and lifestyle relevance," said Cesar Herrera, CEO of KRTL Holding Group Inc. "It’s not only a formulation rooted in health science but also a brand with a strong cultural footprint in Bolivia and a compelling case for expansion."
The ELIXIR lineup includes flavors such as Berry, Arándano, Citrus Punch, Tropical Flavor, Mango Zero (no sugar), and Electro Mandarina in sachet format. The variety of packaging—from single-serve sachets to sleek 625ml bottles—makes ELIXIR suitable for retail shelves, on-the-go consumption, and hospitality applications.
KRTL Biotech is preparing to initiate structured pathways for international market introduction, including regulatory entry into the United States. The U.S. market for hydration solutions, functional wellness beverages, and alcohol recovery aids continues to expand, offering strong demand signals for ELIXIR's unique formulation and branding. As part of this strategy, KRTL Biotech is assessing packaging compliance, ingredient disclosures, and permissible health claims to align with FDA labeling requirements. In parallel, the Company is also developing an import framework and market positioning strategy to support commercial rollout once regulatory alignment is complete.
"As a company rooted in both science and innovation, we’re proud to see ELIXIR emerge as a household name in Bolivia," said Patricia Wilstermann, CEO of SIGMA. "Its evolution from a pharmaceutical concept to a cultural staple represents exactly the kind of product innovation we aim to scale globally."
"We see ELIXIR as more than a product—it’s a proven platform for wellness and recovery," said Daniel Bishop, CEO of KRTL Biotech. "With real-world adoption and scalable production already in place, it offers us a clear path to enter functional beverage markets globally."
For more on ELIXIR, visit the brand's Instagram at @elixir.bo or follow them on Facebook at facebook.com/elixir.
About KRTL Holding Group, Inc.
KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.
About KRTL Biotech, Inc.
KRTL Biotech, Inc. focuses on building scalable life-science operations that prioritize quality, compliance, and innovation. The company aims to expand its international footprint while maintaining rigorous U.S. reporting and regulatory standards.
About Industria Químico Farmacéutica SIGMA Corp SRL
SIGMA is a Bolivian pharmaceutical manufacturer with more than five decades of experience in formulation, quality manufacturing, and commercialization of essential and complementary health products, including pharmaceuticals and nutraceuticals.
For more information:
www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com | www.sigmacorp.com.bo/en/about
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “will,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. These risks and uncertainties include, but are not limited to, changes in regulatory requirements, market conditions, and other factors described in the Company’s filings. Additional information concerning risks and uncertainties that could materially affect KRTL’s business and financial results is included in the Company’s filings with the OTC Markets and, where applicable, the SEC. You should not place undue reliance on forward-looking statements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
www.krtlholding.com info@krtlholding.com www.krtlbiotech.com info@krtlbiotech.com www.krtl-icc.com info@krtl-icc.com
FAQ
What is KRTL's ELIXIR product and what makes it unique?
How many retail locations carry KRTL's ELIXIR in Bolivia?
What flavors of ELIXIR does KRTL currently offer?
What are KRTL's plans for ELIXIR's international expansion?
Where is ELIXIR manufactured?
